Perthera Inc. and Blue Faery Announce Their Partnership Against Liver Cancer
McLean, VA, February 20, 2018 --(PR.com)-- Perthera, Inc., the leading Therapeutics Intelligence Company™, has announced its partnership with Blue Faery, the leading Hepatocellular Carcinoma advocacy group in the US, with the goal to provide liver cancer patients with therapeutic treatment options precisely matched to their individual cancers.
“At Perthera, we are dedicated to helping physicians and patients find the best treatment options for their specific cancer type in their treatment decision-making process. That’s why we are extremely pleased to work with Andrea and her team at Blue Faery. In joining forces with Blue Faery, together we will bring a significant and effective new tool to physicians, hospitals, and patients across the US to fight liver cancer with the Perthera Report.” - Neal G. Koller, President & CEO, Perthera, Inc.
Hepatocellular Carcinoma is the fourth most common cancer in the world, and the second most common cause of cancer deaths worldwide. Perthera and Blue Faery’s partnership will allow Blue Faery affiliated patients, their physicians and hospitals to gain access to the Perthera Report™ which provides precisely matched therapeutic options ranked for the highest probability of best outcome.
"We are thrilled to partner with Perthera," said Blue Faery Founder and President Andrea Wilson. "We believe precision medicine is the future and helping patients understand their liver cancer tumors is necessary to ensure they receive the best possible treatments."
It is estimated that approximately 41,000 new cases of liver cancer will be diagnosed in 2018. With Hepatocellular Carcinoma accounting for approximately 84% of all liver cancers, affected patients can find community and support with Blue Faery, and oncologists can quickly determine the best treatment options for their patients with Perthera.
About Perthera, Inc.
Perthera is the leading Therapeutic Intelligence Company improving outcomes through A.I. and data driven cancer therapy recommendations for any patient anywhere www.perthera.com
About Blue Faery: The Adrienne Wilson Liver Cancer Association
Blue Faery’s mission is to prevent, treat and cure primary liver cancer, specifically Hepatocellular Carcinoma, through research, education and advocacy. To learn more visit http://www.bluefaery.org/
Contact Information:
Phil Robertson
+1 (703) 286-0780
phil.robertson@perthera.com
Safe Harbor Statement:
The statements in the press release that relate to Perthera, Inc. (the “Company”) expectations with regard to the future impact on the Company's results from new products in development and any other statements not constituting historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties which could cause the Company's actual operating results, performance, business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.
“At Perthera, we are dedicated to helping physicians and patients find the best treatment options for their specific cancer type in their treatment decision-making process. That’s why we are extremely pleased to work with Andrea and her team at Blue Faery. In joining forces with Blue Faery, together we will bring a significant and effective new tool to physicians, hospitals, and patients across the US to fight liver cancer with the Perthera Report.” - Neal G. Koller, President & CEO, Perthera, Inc.
Hepatocellular Carcinoma is the fourth most common cancer in the world, and the second most common cause of cancer deaths worldwide. Perthera and Blue Faery’s partnership will allow Blue Faery affiliated patients, their physicians and hospitals to gain access to the Perthera Report™ which provides precisely matched therapeutic options ranked for the highest probability of best outcome.
"We are thrilled to partner with Perthera," said Blue Faery Founder and President Andrea Wilson. "We believe precision medicine is the future and helping patients understand their liver cancer tumors is necessary to ensure they receive the best possible treatments."
It is estimated that approximately 41,000 new cases of liver cancer will be diagnosed in 2018. With Hepatocellular Carcinoma accounting for approximately 84% of all liver cancers, affected patients can find community and support with Blue Faery, and oncologists can quickly determine the best treatment options for their patients with Perthera.
About Perthera, Inc.
Perthera is the leading Therapeutic Intelligence Company improving outcomes through A.I. and data driven cancer therapy recommendations for any patient anywhere www.perthera.com
About Blue Faery: The Adrienne Wilson Liver Cancer Association
Blue Faery’s mission is to prevent, treat and cure primary liver cancer, specifically Hepatocellular Carcinoma, through research, education and advocacy. To learn more visit http://www.bluefaery.org/
Contact Information:
Phil Robertson
+1 (703) 286-0780
phil.robertson@perthera.com
Safe Harbor Statement:
The statements in the press release that relate to Perthera, Inc. (the “Company”) expectations with regard to the future impact on the Company's results from new products in development and any other statements not constituting historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties which could cause the Company's actual operating results, performance, business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.
Contact
Perthera, Inc.
Phil Robertson
703-286-0780
www.perthera.com
Phil Robertson
703-286-0780
www.perthera.com
Contact
Multimedia
Categories